Monday, August 28, 2023
ImmunoGen announced that it has entered into collaboration with Takeda Pharmaceuticals for the development and commercialisation of ELAHERE (mirvetuximab soravtansine-gynx) in Japan.
Under the collaboration and licence agreement, ImmunoGen will receive an upfront payment and additional payments based on the conversion of US Food and Drug Administration (FDA) accelerated approval of ELAHERE in platinum-resistant ovarian cancer to full approval.
ImmunoGen will retain exclusive production rights and will supply the product for development and commercial use in Japan. On the other hand, Takeda will hold an exclusive licence to develop and commercialise ELAHERE in Japan and will take responsibility for regulatory filings and obligations.
The Phase 3 MIRASOL trial findings highlight the promising prospects of ELAHERE as a potential groundbreaking treatment for this debilitating condition. The strategic partnership with ImmunoGen is poised to deliver substantial benefits to patients in Japan.
ELAHERE® (mirvetuximab soravtansine-gynx) is a novel ADC that includes a folate receptor alpha-binding antibody, cleavable linker, and the DM4 payload, a potent tubulin inhibitor for targeted cancer cell destruction.
ELAHERE is recommended for adult patients diagnosed with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This treatment is applicable following one to three earlier systemic therapies. The selection of patients is based on a FDA-approved test.
